Ortho Regenerative Technologies entered into a collaborative Material Transfer Agreement to evaluate a commercial product from an unnamed orthopaedic company partner for use in conjunction with Ortho’s Ortho-R biopolymer matrix. The study is slated to complete within 2019.
Ortho RTi’s RESTORE technology is a chitosan-based muco-adhesive that acts as a biodegradable scaffold that can retain any type of bioactive material, prolonging its therapeutic effect. Ortho-R can be mixed with platelet-rich plasma to deliver biologics to increase the healing in injured tendons, meniscus, ligaments and cartilage. The polymer/biologic hybrid combination can be directly applied into the site of injury without significantly extending O.R. time.
“This agreement is fitting with our strategy of working with other companies to assess whether our proprietary biopolymer platform could be used in conjunction with their products for uses outside of our core focus. It also provides us with a third-party validation of our platform and dramatically increases commercial market opportunities,” said Claude LeDuc, President and Chief Executive Officer of Ortho RTi. “Our preliminary findings suggest that the combination of these two products could be very useful in treating the intended clinical problem. This MTA will lead to further studies to confirm these effects as well as ascertain what adjustments, if any, need to be made in order to move forward with an optimum product combination.”
Ortho Regenerative Technologies entered into a collaborative Material Transfer Agreement to evaluate a commercial product from an unnamed orthopaedic company partner for use in conjunction with Ortho's Ortho-R biopolymer matrix. The study is slated to complete within 2019.
Ortho RTi's RESTORE technology is a chitosan-based...
Ortho Regenerative Technologies entered into a collaborative Material Transfer Agreement to evaluate a commercial product from an unnamed orthopaedic company partner for use in conjunction with Ortho’s Ortho-R biopolymer matrix. The study is slated to complete within 2019.
Ortho RTi’s RESTORE technology is a chitosan-based muco-adhesive that acts as a biodegradable scaffold that can retain any type of bioactive material, prolonging its therapeutic effect. Ortho-R can be mixed with platelet-rich plasma to deliver biologics to increase the healing in injured tendons, meniscus, ligaments and cartilage. The polymer/biologic hybrid combination can be directly applied into the site of injury without significantly extending O.R. time.
“This agreement is fitting with our strategy of working with other companies to assess whether our proprietary biopolymer platform could be used in conjunction with their products for uses outside of our core focus. It also provides us with a third-party validation of our platform and dramatically increases commercial market opportunities,” said Claude LeDuc, President and Chief Executive Officer of Ortho RTi. “Our preliminary findings suggest that the combination of these two products could be very useful in treating the intended clinical problem. This MTA will lead to further studies to confirm these effects as well as ascertain what adjustments, if any, need to be made in order to move forward with an optimum product combination.”
Copy to clipboard 
